PT010

DRUG2 trials

Sponsors

Pearl Therapeutics, Inc.

Conditions

COPDChronic Obstructive Pulmonary Disease

Phase 1

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

CompletedNCT02189304

Pearl Therapeutics, Inc.COPD

Start: 2014-06-01End: 2014-09-01Updated: 2018-06-13

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

CompletedNCT03250182

Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disease

Start: 2017-08-11End: 2017-12-07Updated: 2021-01-29

Related Papers

Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects.

2020-10-013 citations

Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.

2019-12-109 citations

Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults

Clinical Pharmacology in Drug Development2018-06-1416 citations